10x Genomics, Inc. (TXG)
After hours:
| Previous close | 22.41 |
| Open | 22.53 |
| Bid | 22.42 x 200 |
| Ask | 22.46 x 200 |
| Day's range | 22.05 - 22.86 |
| 52-week range | 21.74 - 63.57 |
| Volume | |
| Avg. volume | 1,637,720 |
| Market cap | 2.684B |
| Beta (5Y monthly) | 1.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.23 |
PR Newswire10x Genomics Launches 5,000-Plex Gene Panel for Xenium
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
ZacksInternational Markets and 10x Genomics (TXG): A Deep Dive for Investors
Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
- PR Newswire
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m. Pacific Time.
